Wahed Invest LLC Purchases 250 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Wahed Invest LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,510 shares of the biopharmaceutical company’s stock after buying an additional 250 shares during the period. Wahed Invest LLC’s holdings in Regeneron Pharmaceuticals were worth $2,639,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. SteelPeak Wealth LLC grew its holdings in shares of Regeneron Pharmaceuticals by 173.0% during the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock valued at $1,148,000 after buying an additional 692 shares during the last quarter. Mizuho Securities USA LLC boosted its stake in Regeneron Pharmaceuticals by 625.5% in the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after acquiring an additional 51,162 shares during the last quarter. Tri Locum Partners LP raised its position in shares of Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after purchasing an additional 8,949 shares during the period. Simplify Asset Management Inc. increased its holdings in Regeneron Pharmaceuticals by 50.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after acquiring an additional 3,231 shares during the period. Finally, Catalytic Wealth RIA LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $1,334,000. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on REGN shares. Royal Bank of Canada cut their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Oppenheimer cut their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Leerink Partnrs cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Morgan Stanley dropped their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, Citigroup started coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, November 14th. They set a “neutral” rating and a $895.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,107.29.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $767.90 on Friday. The firm’s 50-day moving average price is $882.14 and its 200-day moving average price is $1,013.01. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a market cap of $84.38 billion, a PE ratio of 19.00, a PEG ratio of 2.89 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 52-week low of $735.95 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.